









市場行情
/
股票
/
nasdaq-arvn
/

Arvinas Inc

ARVN

12.160USD

-0.010-0.08%

收盤 12/26, 16:00（美東）報價延遲15分鐘

860.93M總市值

虧損本益比TTM



Arvinas Inc

12.160

-0.010-0.08%

概覽公司財務分析

概覽

公司

財務

分析

關於 Arvinas Inc 公司

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Arvinas Inc簡介



公司代碼ARVN

公司名稱Arvinas Inc

上市日期Sep 27, 2018

CEODr. John G. Houston, Ph.D.

員工數量430

證券類型Ordinary Share

年結日Sep 27

公司地址5 Science Park

城市NEW HAVEN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編06511-1966

電話12035351456

網址https://www.arvinas.com/

公司代碼ARVN

上市日期Sep 27, 2018

CEODr. John G. Houston, Ph.D.

Arvinas Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

Mr. Edward (Ted) Kennedy, Jr.

Independent Director

Ms. Linda C. Bain

Independent Director

Mr. Andrew Saik

Chief Financial Officer, Treasurer

Dr. Laurie Smaldone Alsup, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

收入明細

FY2025Q2

FY2025Q1

FY2024

FY2023

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

22.40M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.05%

Pfizer Inc

5.38%

D. E. Shaw & Co., L.P.

5.30%

Logos Global Management LP

3.89%

其他

64.05%

持股股東

佔比

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.05%

Pfizer Inc

5.38%

D. E. Shaw & Co., L.P.

5.30%

Logos Global Management LP

3.89%

其他

64.05%

股東類型

持股股東

佔比

Investment Advisor

38.86%

Hedge Fund

26.19%

Investment Advisor/Hedge Fund

19.72%

Venture Capital

6.56%

Corporation

5.38%

Research Firm

4.23%

Individual Investor

2.59%

Pension Fund

0.46%

Bank and Trust

0.31%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

513

61.93M

168.36%

-2.99M

2025Q3

525

64.92M

150.53%

-4.18M

2025Q2

518

67.55M

122.76%

+4.71M

2025Q1

504

63.19M

117.99%

-22.92M

2024Q4

484

75.18M

115.79%

+228.04K

2024Q3

476

75.20M

114.63%

+1.35M

2024Q2

469

73.21M

109.58%

+2.16M

2024Q1

476

70.86M

103.71%

+13.21K

2023Q4

483

66.87M

80.36%

+15.93M

2023Q3

458

50.77M

99.64%

+2.00M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.38M

12.78%

+1.03M

+12.34%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.26M

7.16%

+221.27K

+4.39%

Jun 30, 2025

Pfizer Inc

3.46M

4.71%

Jun 30, 2025

D. E. Shaw & Co., L.P.

2.15M

2.93%

+2.15M

Jun 30, 2025

Logos Global Management LP

4.80M

6.54%

+1.50M

+45.45%

Aug 18, 2025

Millennium Management LLC

1.90M

2.59%

+587.75K

+44.85%

Jun 30, 2025

State Street Investment Management (US)

1.73M

2.36%

-163.87K

-8.64%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.59M

2.16%

+48.30K

+3.14%

Jun 30, 2025

New Leaf Venture Partners LLC

1.59M

2.16%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.76%

State Street SPDR S&P Pharmaceuticals ETF

1.65%

Virtus LifeSci Biotech Clinical Trials ETF

0.91%

Invesco NASDAQ Future Gen 200 ETF

0.7%

iShares U.S. Pharmaceuticals ETF

0.28%

Federated Hermes MDT Small Cap Core ETF

0.24%

Zacks Small/Mid Cap ETF

0.22%

iShares Health Innovation Active ETF

0.16%

ProShares Ultra Nasdaq Biotechnology

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.1%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.76%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.65%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.91%

Invesco NASDAQ Future Gen 200 ETF

佔比0.7%

iShares U.S. Pharmaceuticals ETF

佔比0.28%

Federated Hermes MDT Small Cap Core ETF

佔比0.24%

Zacks Small/Mid Cap ETF

佔比0.22%

iShares Health Innovation Active ETF

佔比0.16%

ProShares Ultra Nasdaq Biotechnology

佔比0.11%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.1%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Arvinas Inc的前五大股東是誰？



Arvinas Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：9.38M
佔總股份比例：12.78%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.26M
佔總股份比例：7.16%。
Pfizer Inc
持有股份：3.46M
佔總股份比例：4.71%。
D. E. Shaw & Co., L.P.
持有股份：2.15M
佔總股份比例：2.93%。
Logos Global Management LP
持有股份：4.80M
佔總股份比例：6.54%。